Trichloroethylene (TCE) Exposure in an Industrial Population

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

John Slevin, University of Kentucky

ClinicalTrials.gov Identifier:

NCT00839514

First received: February 6, 2009

Last updated: June 6, 2012

Last verified: June 2012

History of Changes

Purpose

This study is to follow-up with workers from a local company that had exposure to TCE that may have symptoms of Parkinson's disease. We hope to learn more about TCE exposure and Parkinson's disease. Eligible participants will be those who participated in previous research study entitled "Survey of Selected Exposures and Neurologic Symptoms in an Industrial Population"

Condition
Parkinson's Disease

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Cross-Sectional
Official Title:	Evaluation of Parkinson Disease Symptoms in Trichloroethylene Exposed Patients in an Industrial Population

Resource links provided by NLM:

Genetics Home Reference related topics: Parkinson disease Perry syndrome

MedlinePlus related topics: Parkinson's Disease

U.S. FDA Resources

Further study details as provided by University of Kentucky:

Enrollment:	27
Study Start Date:	February 2009
Study Completion Date:	August 2009
Primary Completion Date:	August 2009 (Final data collection date for primary outcome measure)

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Follow-up with individuals who previously particpated in the research study entitled "Survey of Selected Exposures and Neurologic Symptoms in an Industrial Population"

Criteria

Inclusion Criteria:

Previous participant in the research study entitled "Survey of Selected Exposures and Neurologic Symptoms in an Industrial Population"

Exclusion Criteria:

Not a participant in the research study entitled "Survey of Selected Exposures and Neurologic Symptoms in an Industrial Population"

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00839514

Locations

United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536-0284

Sponsors and Collaborators

University of Kentucky

Investigators

Principal Investigator:

John T Slevin, MD

University of Kentucky

More Information

Publications:

Gash DM, Rutland K, Hudson NL, Sullivan PG, Bing G, Cass WA, Pandya JD, Liu M, Choi DY, Hunter RL, Gerhardt GA, Smith CD, Slevin JT, Prince TS. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol. 2008 Feb;63(2):184-92.

Responsible Party:	John Slevin, Principal investigator, University of Kentucky
ClinicalTrials.gov Identifier:	NCT00839514 History of Changes
Other Study ID Numbers:	08-0301
Study First Received:	February 6, 2009
Last Updated:	June 6, 2012
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Kentucky:

Parkinson's disease
Trichloroethylene

Additional relevant MeSH terms:

Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Trichloroethylene

Anesthetics, Inhalation
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 16, 2013

To Top